Basis of Presentation and Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2014

Accounting Policies [Abstract]

Schedules of Concentration of Risk, by Risk Factor

Customers whose revenue accounted for 10% or more of total revenues were as follows:

	Three Months Ended June 30,				Six months ended June 30,
	2014		2013		2014		2013
Exela (related party)	32	%	*		30	%	*
Merck	28	%	65	%	25	%	50	%
Novartis	12	%	—	%	20	%	*
Arch	—	%	—	%	—	%	12	%

* less than 10%

Securities not included in the net loss per common share calculations

The following common equivalent shares were not included in the computation of diluted net loss per share because their effect was anti-dilutive:

	Three Months Ended June 30,		Six Months Ended June 30,
	2014	2013	2014	2013
Options to purchase common stock	3,888	4,996	3,888	4,996
Restricted stock units/awards	2,504	1,827	2,504	1,827
Performance stock units	722	—	722	—
Warrants to purchase common stock	75	75	75	75
Total shares excluded as anti-dilutive	7,189	6,898	7,189	6,898